Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Allena Pharmaceuticals, Inc. | alna-ex321_6.htm |
| EX-31.2 - EX-31.2 - Allena Pharmaceuticals, Inc. | alna-ex312_9.htm |
| EX-31.1 - EX-31.1 - Allena Pharmaceuticals, Inc. | alna-ex311_7.htm |
| EX-10.11 - EX-10.11 DIRECTORS COMPENSATION - Allena Pharmaceuticals, Inc. | alna-ex1011_173.htm |
| 10-K - 2020 10-K ANNUAL REPORT - Allena Pharmaceuticals, Inc. | alna-10k_20201231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
|
1. |
Registration Statement (Form S-8, No. 333-221306) pertaining to the 2011 Stock Incentive Plan, the 2017 Stock Option and Incentive Plan, and the 2017 Employee Stock Purchase Plan of Allena Pharmaceuticals, Inc., |
|
|
2. |
Registration Statement (Form S-8, No. 333-223939) pertaining to the 2017 Stock Option and Incentive Plan and the 2017 Employee Stock Purchase Plan of Allena Pharmaceuticals, Inc., |
|
|
3. |
Registration Statements (Form S-3, Nos. 333-228656 and 333-250992) of Allena Pharmaceuticals, Inc., and |
|
|
4. |
Registration Statements (Form S-8, Nos. 333-230127 and 333-237218) pertaining to the 2017 Stock Option and Incentive Plan of Allena Pharmaceuticals, Inc.; |
of our report dated March 11, 2021, with respect to the consolidated financial statements of Allena Pharmaceuticals, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 11, 2021